|
BLDV, PWRM, CVIT, VG, September 3 Stocks to Watch from OTCPicks.com
(M2 PressWIRE Via Acquire Media NewsEdge) Our Stocks to Watch tomorrow include Blue Diamond Ventures Inc. (OTC: BLDV), Power3 Medical Products Inc. (OTCBB: PWRM), Cavit Sciences Inc. (OTC: CVIT) and Vonage Holdings Corp. (NYSE: VG).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
BLUE DIAMOND VENTURES INCORPORATED (OTC: BLDV) "Up 250.00% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/BLDV.php
Blue Diamond Ventures, Inc. is an agricultural company, and through its affiliate, Blue Diamond Ventures Biofuels, LLC, conducts business as a biofuels company with operations in the U.S. and future endeavors in the Caribbean and Ethiopia.
BLDV News:
September 2 - Blue Diamond Ventures Moves Toward Wind Turbine Agreement, Following Highly Favorable Wind Study Results
Following highly favorable wind study results in Huerfano County, Colorado, Blue Diamond Ventures, Inc. (OTC: BLDV), through its affiliate Blue Diamond Ventures Renewables, LLC, and its joint venture partner Freedom Works, LLC, have moved toward a wind turbine supply agreement and final designs to construct a 198 megawatt wind project plus 68 miles of transmission line.
On-site met tower wind data for the joint venture's Huerfano Project will be completed on September 8, 2009. The data for the project is available at:
www.engr.colostate.edu/ALP/ALP_62_Sheep_Mountain.htm.
The new study is the culmination of five years of wind data studies throughout Huerfano County and proves the existence of resource at the Colorado Wind Generation Resource Area #8 as described by the Governor's Energy Office. The project's transmission line has been identified by Colorado Governor Bill Ritter as the number one transmission priority in the State of Colorado.
"Despite the current economic environment, we have worked extremely hard to meet our goals and increase shareholder value," said Blue Diamond CEO John Quincey Moaning.
Last year, the company established a goal to implement its renewable generation portfolio - the foundation of which is the development of basic infrastructure to facilitate timely transmission, substation and wind turbine generator installations in the Midwestern United States.
POWER 3 MEDICAL PRODUCTS INCORPORATED (OTCBB: PWRM) "Up 86.54% on Wednesday"
Detailed Quote: www.otcpicks.com/quotes/PWRM.php
Power3 Medical Products Inc. is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.
PWRM News:
September 2 - Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson's Disease
On-line Publication of Biomarker Panel that Forms Basis for NuroPro PD Diagnostic Test
Transgenomic, Inc. (OTCBB: TBIO) and Power3 Medical Products, Inc. (OTCBB: PWRM) announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson's disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood serum samples.
The analytic technology forms the basis for the NuroProPD test for PD being commercialized by Transgenomic as per a licensing/collaboration agreement with Power3 Medical signed in early 2009. The publication of the peer-reviewed article is a significant validation milestone in the ongoing clinical development of the NuroProPD diagnostic assay.
The article describes the use of analytically validated quantitative 2D gel electrophoresis to identify protein biomarkers for diagnosing PD using serum from routinely collected blood samples. 57 protein biomarkers, which had been discovered using retrospective blood serum samples from various neurodegenerative diseases, were then applied specifically to PD in a prospective clinical investigation using freshly collected blood serum from PD patients and age-matched normal controls. A multi-variate statistical method, stepwise linear discriminant analysis, selected a combination of 21 of the biomarkers as optimal to distinguish PD patients from controls. When applied to the PD samples, the 21-protein set had sensitivity of 93.3% (52 of 56 PD correctly classified) and specificity of 92.9% (28 of 30 controls correctly classified); 15 of 15 patients with mild and 28 of 30 with moderate to severe symptoms were correctly classified, as were all 6 PD samples from an independent site.
"We are enthusiastic about the acceptance of our paper in this established peer-reviewed scientific journal. It represents independent external validation of the clinical data, and so increases the confidence that we have in NuroProPD to be a meaningful tool for the diagnosis of Parkinson's disease, especially early in its course," said Craig Tuttle, CEO of Transgenomic. "We are completing the clinical validation of the assay in our CLIA-certified molecular testing laboratory and will be launching the assay in the very near future."
"In the U.S., there are an estimated 1.5 million individuals with Parkinson's disease. Unfortunately, by the time patients are given a probable diagnosis, many have already suffered substantial and irreparable brain damage, rendering treatment less effective," said Dr. Ira Goldknopf, President and CSO of Power3 Medical and lead author on the paper. "The fact that these results were obtained using fresh blood serum, in the same way that the test will be performed in a clinical diagnostic setting, provides further support for their robustness and their commercial value."
Clinical investigators in the study were Dr. Katerina Markopoulou of the University of Thessaly, Greece, Drs. Marwan Sabbagh and Holly Shill of Banner Sun Health Research Institute, Sun City, Arizona, and Dr. Stanley Appel of the Texas Methodist Health System, Houston.
ABOUT TRANSGENOMIC, INC.
Transgenomic, Inc. (OTCBB: TBIO) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,450 systems have been shipped to customers in more than 30 countries. The SURVEYOR Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared to manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomic Services is a CRO for pharmacogenomic, translational research and clinical trials.
CAVIT SCIENCES INCORPORATED (OTC: CVIT) "Up 32.43% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/CVIT.php
Cavit Sciences, Inc. ("Cavit") is a biotechnology company that owns a unique supplement line with products that enhance, improve, maintain and support the body by beneficially affecting various conditions. The supplement products will be showcased on this website with complete descriptions and details. In addition, the Company is engaged in developing treatments and prevention for viral infections, opportunistic infections, related diseases and the immune system. It currently owns twelve patent applications and its strategy is to develop and commercialize these intellectual property rights.
CVIT News:
September 1 - Cavit Sciences Inc. Enters Into Contracts with McCoy Enterprises LLC to Finalize Merger Agreement
Cavit Sciences Inc. (OTC: CVIT) management has been negotiating with Randall McCoy and Joe Connell principle owners of McCoy Enterprises LLC to merge our companies. Maggie Smyth, CEO of Cavit states, "We all feel very good about this fit so we have added a breakup clause to show our commitment to each other".
"McCoy" has been working on getting final FDA approval for their Cultured Skin Substitute (PermaDerm). Their CSS has already been given Orphan Drug Status by the FDA and will be indicated for children under 12 years old with 50% or more body surface burned.
Along with the merger agreement "Cavit" and "McCoy" are working together to secure a $16,000,000 Loan to facilitate and get final FDA approval for the first indication of "PermaDerm" this should be accomplished in the next few days.
Maggie Smyth interim CEO of Cavit states, "This agreement to finalize our merger has been long and hard, but both sides realize that as a team we see a bright and prosperous future for the Shareholders of our Company and the patients who will benefit most from the development of "PermaDerm".
Joe Connell, Chief Operations Officer of McCoy, also states "We have taken all serious efforts to see that 'PermaDerm' gets to market as fast as possible for the people that need it. As we grow and develop new indications for our CSS we see our mergered companies as a leader in Skin Cell Regeneration. We expect to have PermaDerm available in 2010 for its first indication."
VONAGE HOLDINGS CORPORATION (NYSE: VG) "Up 19.58% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/VG.php
Vonage Holdings Corp., through its subsidiaries, provides broadband Voice over Internet Protocol services to residential and small business and home office customers. It offers various features, such as call waiting, caller ID with name, call forwarding, and voicemail. The company also provides area code selection, number portability, online account management, and personalized Web-enabled voicemail. In addition, it offers services, including Vonage visual voicemails, virtual phone numbers, toll free numbers, and residential and business fax services, as well as Vonage SoftPhone, a software application that is downloaded and installed on computers, laptops, and WiFi-enabled personal digital assistant devices, which enables user to use a computer as a telephone. Further, the company offers Vonage-enabled devices, such as Vonage V-Portal to connect up to two Vonage lines through a high-speed Internet connection and includes a networking router; analog telephone adapters, which convert analog audio signals into digital data packets for transmission over the Internet; integrated adapters and wireless routers; Vonage Bundled Cordless Phone; V-phone, a USB compatible device; and Vonage Companion, a downloadable softphone that can be loaded on a laptop or PC. As of December 31, 2008, it had approximately 2.6 million subscriber lines in service. The company was incorporated in 2000 and is headquartered in Holmdel, New Jersey.
VG News:
September 1 - Vonage Obtains Application Approval for iTunes App Store
Vonage (NYSE: VG) has announced that Apple approved its mobile application for iPhone and iPod Touch. Vonage is currently conducting a beta test and general availability will be announced at a later date.
This new service, along with the recent launch of the Vonage World unlimited calling plan, continues Vonage's heritage of using innovative technology to create significant value for its current and future customers.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ InfoTech Spotlight's Homepage ]
|
